A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
A phase 3 trial of 9MW2821 in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.
Overview
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer is a phase 3 interventional study registered as NCT06196736 by Mabwell (Shanghai) Bioscience Co., Ltd., with 432 participants planned, started 2023-12-29 and due to reach its primary completion in 2026-09. Interventions recorded: 9MW2821 and Chemotherapy.
Similar pages
not linked directly; found by shared links- TrialIntravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialLEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialSafety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Shares Bladder & urothelial cancer and the tag pipeline.